Exhibit 10.2
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.
**UNIVERSITY of PENNSYLVANIA
First Amendment to License Agreement
This First Amendment to the License Agreement effective as of June 7, 2019 (this *“First Amendment’), is *made by and between The Trustees of the University of Pennsylvania *(“Penn”) *and Kira Pharmaceuticals *(“Licensee”) *and amends the License Agreement between the parties, dated June 9, 2017 (the *“License Agreement”; *Penn agreement reference [***]).
BACKGROUND
The License Agreement relates to certain intellectual property developed by Dr. Wenchao Song of Penn’s Perelman School of Medicine, which intellectual property is the subject of patents or patent applications and is related to antibody therapeutics against complement proteins C5, factor D and C5a (Penn docket references [***], [***] and [***]). Penn developed certain new technologies relating to treatment of complement mediated diseases (Penn docket references: [***], [***], [***] and [***]) through the sponsored research agreement between Penn and Licensee, dated June 9, 2017 (the “Sponsored Research Agreement”; Penn reference [***]) Company desires to obtain rights to such new technologies under the License Agreement. The parties wish to amend the License Agreement to reflect these changes.
Now, therefore, the parties hereby agree as follows:
| 1) | Exhibit A of the License Agreement is hereby deleted and replaced with **Schedule A-1 attached hereto. |
| 2) | Section 1.19 of the License Agreement shall be deleted and replaced with the following: |
“1.19 “Patent Family” means the Penn Patent Rights listed in Exhibit A that are associated with discrete patent families, namely, the “fD Patent Family” which means Penn Patent Rights with the Penn reference [***]; the “C5 Patent Family” which means Penn Patent Rights with the Penn reference [***], [***], [***], [***] and [***]; and the “C5a Patent Family” which means Penn Patent Rights with the Penn reference [***] (each of ED Patent Family, C5 Patent Family and C5a Patent Family, a “Patent Family” and collectively, the “Patent Families”).”
| 3) | Section 6.2 of the License Agreement shall be deleted and replaced with the following: |
“Representation of Licensee. Licensee represents and warrants that it shall have closed a financing prior to or as of June 30, 2017 pursuant to which it shall have raised not less than [***] for the operations of Licensee.”
To the extent that Licensee was in breach of Section 6.2 of the License Agreement prior to the amendment of such section pursuant to this First Amendment, Penn hereby irrevocably waives such breach and any and all remedies, whether under the License Agreement or otherwise, which Penn may have with respect to such breach.
| 4) | This First Amendment, together with the License Agreement, constitute the entire agreement between the parties. All other terms and provisions of the License Agreement, except as expressly amended by this First Amendment, remain in full force and effect. |
| 5) | This First Amendment may be executed in two or more counterparts, each of which shall be deemed an original and together shall be deemed one and the same instrument. |
[Signature page follows]
IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this First Amendment to be executed by their duly authorized representatives.
| THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | ||
| By: | */s/ *Benjamin Dibling, Ph.D. | |
| Name: | Benjamin Dibling, Ph.D*.* | |
| Title | Executive Director of Licensing, Penn Center for Innovation | |
| Date: | August 12, 2019 | |
| Kira Pharmaceuticals | ||
| By: | */s/ *Gonghua Pan | |
| Name: | Gonghua Pan | |
| Title: | Director | |
| Date: |
Schedule A-1
Exhibit A
Penn Patent Rights
[***]
3